Skip to main content

CORRECTION article

Front. Pediatr., 15 February 2021
Sec. Pediatric Neurology
This article is part of the Research Topic New Therapeutic Options for Rare Diseases View all 21 articles

Corrigendum: Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

\nSilvia TenembaumSilvia Tenembaum1E. Ann Yeh
E. Ann Yeh2*The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC)&#x; The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC)
  • 1Department of Neurology, National Pediatric Hospital Dr. J. Garrahan, Buenos Aires, Argentina
  • 2Division of Neurology, Department of Pediatrics, SickKids Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

A Corrigendum on
Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

by Tenembaum, S., Yeh, E. A., and The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC) (2020). Front. Pediatr. 8:339. doi: 10.3389/fped.2020.00339

In the original article, there was a mistake in Table 3 as published. The administration form of satralizumab is “SC” not “IV.” The corrected Table 3 appears below.

TABLE 3
www.frontiersin.org

Table 3. Immunosuppressive molecules for attack prevention in NMOSD.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: pediatric, neuroinflammation, NMOSD, MOG, treatment, diagnosis

Citation: Tenembaum S, Yeh EA and The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC) (2021) Corrigendum: Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front. Pediatr. 8:642203. doi: 10.3389/fped.2020.642203

Received: 15 December 2020; Accepted: 16 December 2020;
Published: 15 February 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Tenembaum, Yeh and The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: E. Ann Yeh, ann.yeh@sickkids.ca

See Appendix for complete list of active GJCF-ICC Members

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.